Af
Affinia
Waltham MAFounded 201950 employees
Private CapbiotechPrivateRare DiseaseNeurology
Platform: Synth AAV
Market Cap
N/A
All Drugs
4
Clinical Trials
6
Failed / Terminated
0
FDA Approved
0
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Gelituximab | AFF-4896 | NDA/BLA | 2 | CDK2 | RSV | ||
| Teranesiran | AFF-6405 | Phase 1 | 1 | WRN | BCCHuntington's | ||
| Lisolemzoparlimab | AFF-956 | Preclinical | 1 | GPRC5D | HS | ||
| Rilunaritide | AFF-5442 | Preclinical | 2 | CD3 | HNSCCSCD |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (5)